GPT and fatty liver disease: Until new evidence accumulates about the best screening methodology in pediatric MASLD, screening with ALT in most settings will remain the main approach to select the subgroup of subjects at increased risk of progression, although the subset of children with hepatic steatosis who have normal liver enzymes will be missed.